SCHEMBL5249506

SCHEMBL5249506

O=C1NC=Cc2ccc(OCCCCOCc3ccccc3)nc2N1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
HRH4 Q9H3N8 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
PKM P14618 1/20 0.33
KCNA3 P22001 1/20 0.33
KCNA5 P22460 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
REN P00797 1/20 0.33
EPHX2 P34913 1/20 0.32
HTT P42858 1/20 0.32
FAAH O00519 1/20 0.32
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
PPARG P37231 1/20 0.32
GRM5 P41594 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5366683 0.73 KCNH2 (0.40) KCNA3KCNA5GRM5
SCHEMBL253025 0.73 DRD2 (0.56)
SCHEMBL5372271 0.71 ALDH1A1 (0.41) ALDH1A1HRH4HRH3PKMTDP1
SCHEMBL5364423 0.69 HTR1A (0.47) ALDH1A1HRH4HRH3KCNA3KCNA5
SCHEMBL5374958 0.69 HRH4 (0.44) HRH4HRH3PKMTDP1L3MBTL1
SCHEMBL2640223 0.65 TSHR (0.70) HRH4HRH3KCNA3TDP1L3MBTL1
SCHEMBL20129054 0.64 TSHR (0.44) HRH4HRH3TDP1L3MBTL1EPHX2
SCHEMBL716935 0.64 TSHR (0.56) ALDH1A1HRH4HRH3TDP1L3MBTL1
SCHEMBL10390255 0.64 FAAH (0.47) ALDH1A1HRH4HRH3TDP1L3MBTL1
SCHEMBL9011595 0.63 TSHR (0.67) HRH4HRH3KCNA3TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869041-A1 TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA Warner-Lambert Company LLC (US) 2007-12-26 EP disclosed
WO-2007116265-A1 PROCESS FOR MAKING A TETRAHYDRO-PYRIDOAZEPIN-8-ONE COMPOUND PFIZER PRODUCTS INC. (US) 2007-10-18 WO disclosed
WO-2007116265-A1 PROCESS FOR MAKING A TETRAHYDRO-PYRIDOAZEPIN-8-ONE COMPOUND PFIZER PRODUCTS INC. (US) 2007-10-18 WO disclosed
US-20060234997-A1 Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia WARNER-LAMBERT COMPANY LLC 2006-10-19 US disclosed
WO-2006103559-A1 TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC (US) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060234997-A1 Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia PTGDR, GRIN2A, PTGDR2 ALDH1A1 826/4885HRH4 452/4885HRH3 1596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.